On Wednesday, First Bancorp (NYSE:FBP)’s shares declined -1.27% to $3.88.
First BanCorp (FBP), the bank holding company for FirstBank Puerto Rico, is happy to declare the results of its 2015 company-run capital stress test (“Dodd-Frank Act Stress Test” or “DFAST”). First BanCorp is required to disclose the results of the DFAST annually, starting with the 2015 test.
Results indicate that, even in the severely adverse scenario presented by the test, First BanCorp’s capital ratios exceed both the regulatory minimum required ratios mandated under Basel III and the well-capitalized thresholds throughout the nine-quarter time horizon.
First BanCorp. operates as the bank holding company for FirstBank Puerto Rico that provides a range of financial products and services to retail, commercial, and institutional clients. Its Commercial and Corporate Banking segment offers commercial real estate and construction loans, and floor plan financings; and cash administration and business administration services, in addition to underwrites bonds and financial advisory services offered to government entities.
Garmin Ltd. (NASDAQ:GRMN)’s shares gained 0.25% to $40.34.
The Garmin Ltd.(GRMN) governing body has built up September 30, 2015 as the installment date for the following profit portion of $0.51 per offer with a record date of September 15, 2015, per the regard some time ago offered at the 2015 yearly shareholders’ meeting. At the 2015 yearly meeting Garmin shareholders, as per Swiss corporate law, endorsed a trade profit in for spendable dough the aggregate sum of $2.04 per offer (subject to conceivable conformity in view of the aggregate sum of the profit in Swiss Francs), payable in four equivalent portions on dates to be controlled by the board in its carefulness.
Garmin Ltd., together with its assistants, plans, creates, makes, and markets hand-held, wrist-based, and convenient and settled mount worldwide situating framework (GPS) empowered items; and other route, correspondence, and data items around the world. It works in five fragments: Automotive/Mobile, Aviation, Marine, Outdoor, and Fitness.
At the end of Wednesday’s trade, Curis, Inc. (NASDAQ:CRIS)‘s shares surged 0.38% to $2.61.
Curis, Inc. (CRIS), a biotechnology organization concentrated on the advancement and commercialization of imaginative medication contender for the treatment of human malignancies, expressed its money related results for the second quarter finished June 30, 2015.
Second Quarter and First Half 2015 Financial Results
Curis expressed a net loss of $8.1 million, or ($0.06) per offer on both an essential and completely weakened premise for the second quarter of 2015, as difference to a net loss of $1.9 million or ($0.02) per offer on both a fundamental and completely weakened premise for the same period in 2014. Curis expressed a net loss of $40 million, or ($0.34) per offer on both a fundamental and completely weakened premise for the six months finished June 30, 2015, as complexity to a net loss of $7.5 million or ($0.09) per offer on both an essential and completely weakened premise for the same period in 2014. The net misfortune for the first 50% of 2015 involves an in-procedure innovative work charge of $24.3 million identified with Curis’ permit concurrence with Aurigene.
Incomes for the second quarter of 2015 were $2.1 million, as differentiation to $4.8 million for the same period in 2014. The decline in incomes was fundamentally because of a diminishing in permit charge incomes because of a $3 million point of reference installment that Curis earned from Genentech/Roche upon accomplishment by Genentech/Roche of certain advancement targets amid the second quarter of 2014. Balancing these declines, eminence incomes recorded on Genentech/Roche’s net offers of Erivedge rose to $2.0 million in the second quarter of 2015 as difference to $1.8 million amid the same period in 2014.
Curis, Inc., a biotechnology organization, takes part in the revelation and advancement of medication contender for the treatment of human malignancies. The organization creates CUDC-907, an oral little atom inhibitor of histone deacetylase and phosphatidylinositol-3-kinase proteins, which is in Phase I clinical trials for cutting edge lymphomas and different myeloma; and HER 2-/ER+ or PR+ bosom malignancy, and NUT midline carcinoma.
Unwired Planet Inc (NASDAQ:UPIP), ended its Wednesday’s trading session with 6.39% gain, and closed at $0.745.
Unwired Planet, Inc. (UPIP) announced that its yearly meeting of shareholders is wanted to occur on December 4, 2015. Shareholders of record as of the end of business on October 6, 2015, the record date for the meeting, will be qualified for vote at the meeting.
Unwired Planet, Inc., a protected innovation authorizing organization, creates licenses that permit cell phones to join with the Internet around the world. As of August 14, 2014, the organization’s patent portfolio embodied around 2,500 issued and pending U.S. furthermore, outside licenses. Its licenses spread different 2G, 3G, and 4G innovations, notwithstanding cloud-based versatile applications and administrations.